Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Prometic to report its third quarter 2016 financial results and hold conference call / webcast

Canada NewsWire November 9, 2016

ProMetic announces closing of Telesta Therapeutics Inc. acquisition

Canada NewsWire October 31, 2016

ProMetic's plasminogen meets primary and secondary end points in pivotal Phase 2/3 trial

Canada NewsWire October 26, 2016

ProMetic's PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes Phase 2 clinical trial

Canada NewsWire October 20, 2016

ProMetic's PBI-4050 Significantly Reduces Liver Fibrosis in Patients with Alström Syndrome

Canada NewsWire October 12, 2016

ProMetic's PBI-4050 Significantly Reduces Liver Fibrosis in Patients with Alström Syndrome

PR Newswire October 12, 2016

ProMetic announces the addition of tympanic membrane perforations (TMPs) to its plasminogen's targeted indications

Canada NewsWire September 6, 2016

ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction

Canada NewsWire August 24, 2016

ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction

PR Newswire August 24, 2016

ProMetic reports second quarter 2016 highlights and financial results

Canada NewsWire August 11, 2016

Prometic completes patients' enrolment in pivotal plasminogen phase 2/3 clinical trial

Canada NewsWire August 11, 2016

ProMetic Completes Adult Patients' Enrolment in Pivotal IVIG Phase 3 Clinical Trial

Canada NewsWire August 9, 2016

Prometic to report its second quarter 2016 financial results and hold conference call / webcast

Canada NewsWire August 2, 2016

Eurofins QTA and Q-Interline announce Collaboration for the Advancement of Infrared Testing

Canada NewsWire August 2, 2016

ProMetic's plasminogen granted Fast Track designation by the US FDA

Canada NewsWire June 13, 2016

ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association's upcoming annual meeting

Canada NewsWire June 9, 2016

ProMetic announces closing of $60 million bought deal offering of common shares

Canada NewsWire May 25, 2016

Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis

Canada NewsWire May 18, 2016

ProMetic Reports its First Quarter 2016 Highlights and Financial Results

Canada NewsWire May 12, 2016

Positive response in kidney and urinary tract to ProMetic's plasminogen treatment in a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA

Canada NewsWire May 11, 2016